CD19

B-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4) (Differentiation antigen CD19) (T-cell surface antigen Leu-12) (CD antigen CD19)

Homo sapiens (Human)

61128

556

Pending Verification

B-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4) (Differentiation antigen CD19) (T-cell surface antigen Leu-12) (CD antigen CD19)

Immunodeficiency, common variable, 3 (CVID3) [MIM:613493]: A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low. {ECO:0000269|PubMed:16672701}. Note=The disease is caused by mutations affecting the gene represented in this entry.

MUTAGEN 309 556 Missing: Abolishes the ability to activate signaling pathways that mediate mobilization of cytoplasmic Ca(2+). Abolishes the ability to restore normal B cell functions and responses to antigenic stimuli. {ECO:0000269|PubMed:9317126}.; MUTAGEN 348 348 Y->F: No effect on the ability to complement impaired B cell development and functions; when associated with F-378. {ECO:0000269|PubMed:12387743}.; MUTAGEN 378 378 Y->F: No effect on the ability to complement impaired B cell development and functions; when associated with F-348. {ECO:0000269|PubMed:12387743}.; MUTAGEN 409 409 Y->F: No effect on the ability to complement impaired B cell development and functions; when associated with F-439. {ECO:0000269|PubMed:12387743}.; MUTAGEN 421 421 Y->F: No effect on the ability to complement impaired B cell development and functions; when associated with F-461. {ECO:0000269|PubMed:12387743}.; MUTAGEN 439 439 Y->F: No effect on the ability to complement impaired B cell development and functions; when associated with F-409. {ECO:0000269|PubMed:12387743}.; MUTAGEN 461 461 Y->F: No effect on the ability to complement impaired B cell development and functions; when associated with F-421. {ECO:0000269|PubMed:12387743}.; MUTAGEN 500 500 Y->F: Strongly reduced tyrosine phosphorylation; when associated with F-531. Abolishes activation of signaling pathways that mediate mobilization of cytoplasmic Ca(2+); when associated with F-531. Abolishes the ability to complement impaired B cell development and functions; when associated with F-531. {ECO:0000269|PubMed:12387743, ECO:0000269|PubMed:7684160, ECO:0000269|PubMed:9382888}.; MUTAGEN 531 531 Y->F: Strongly reduced tyrosine phosphorylation; when associated with F-500. Abolishes activation of signaling pathways that mediate mobilization of cytoplasmic Ca(2+); when associated with F-500. Abolishes the ability to complement impaired B cell development and functions; when associated with F-500. {ECO:0000269|PubMed:12387743, ECO:0000269|PubMed:7684160, ECO:0000269|PubMed:9382888}.

MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPLGPEDEDSFSNAESYENEDEELTQPVARTMDFLSPHGSAWDPSREATSLGSQSYEDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGPDPAWGGGGRMGTWSTR

Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed:2463100, PubMed:1373518, PubMed:16672701). Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701). Is not required for early steps during B cell differentiation in the blood marrow (PubMed:9317126). Required for normal differentiation of B-1 cells (By similarity). Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:2463100, PubMed:1373518). Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701). {ECO:0000250|UniProtKB:P25918, ECO:0000269|PubMed:12387743, ECO:0000269|PubMed:1373518, ECO:0000269|PubMed:16672701, ECO:0000269|PubMed:2463100, ECO:0000269|PubMed:9317126, ECO:0000269|PubMed:9382888}.

Alternative sequence (1); Beta strand (18); Chain (1); Disulfide bond (3); Domain (2); Frameshift (1); Glycosylation (5); Helix (2); Modified residue (7); Mutagenesis (9); Natural variant (2); Sequence conflict (6); Signal peptide (1); Topological domain (2); Transmembrane (1); Detected on marginal zone and germinal center B cells in lymph nodes (PubMed:2463100). Detected on blood B cells (at protein level) (PubMed:2463100, PubMed:16672701). {ECO:0000269|PubMed:16672701, ECO:0000269|PubMed:2463100}.

B-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4) (Differentiation antigen CD19) (T-cell surface antigen Leu-12) (CD antigen CD19)

Recombinant

HEK293

Lyophilized

7.4-7.5

Sterile-filtered colorless solution

1mg/ml

Standard

PBS

SDS-PAGE

> 98%

RP-HPLC

-20°C

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.